GEA
UTHR icon

Glen Eagle Advisors’s United Therapeutics UTHR Stock Holding History

Glen Eagle Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25
Closed -$6.95K – 1207
2022
Q4 		$6.95K Buy
25
+7
+39% +$1.77K ﹤0.01% 663
2022
Q3 		$3.77K Buy
+18
New +$4.02K ﹤0.01% 753

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Glen Eagle Advisors's UTHR Position: Q1 2023 in Review

Glen Eagle Advisors sold out of United Therapeutics (UTHR) in Q1 2023, closing a stake of 25 shares — an estimated $6.95K sold.

Glen Eagle Advisors first reported a position in UTHR in Q3 2022 and held it in 2 quarters. The position peaked at $6.95K in Q4 2022. 505 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

  • Glen Eagle Advisors reported no remaining United Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Glen Eagle Advisors sold 25 United Therapeutics shares in Q1 2023, an estimated $6.95K.
  • Glen Eagle Advisors first reported a position in United Therapeutics in Q3 2022 and held it in 2 quarters.
  • Glen Eagle Advisors's United Therapeutics position peaked at $6.95K in Q4 2022.
  • 505 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on Glen Eagle Advisors's 13F filing for Q1 2023, filed 13 Aug 2024.